Literature DB >> 24211290

Factors that contribute to hypertransaminasemia in patients with celiac disease or functional gastrointestinal syndromes.

Barbara Zanini1, Roberta Baschè1, Alice Ferraresi1, Marie Graciella Pigozzi1, Chiara Ricci1, Francesco Lanzarotto1, Vincenzo Villanacci2, Alberto Lanzini3.   

Abstract

BACKGROUND & AIMS: Transaminasemia develops via different pathways in patients with celiac disease; no information is available on risk factors specifically attributable to celiac disease.
METHODS: We analyzed data collected from consecutive patients referred from January 1997 through December 2009 to the celiac disease clinic at the Spedali Civili of Brescia, Italy. We assessed the factors affecting hypertransaminasemia in 683 patients with celiac disease (based on serologic and biopsy analysis, cohort A; 34 ± 14 years of age) and 304 with functional syndromes (cohort B; 37 ± 13 years of age).
RESULTS: Hypertransaminasemia was detected in 138 patients in cohort A (20%). It was associated with malabsorption (odds ratio [OR], 2.22; P = .004), diarrhea (OR, 1.72; P = .005), and increasing severity of mucosal lesion (Marsh-Oberhuber class; OR, 1.46; P = .001) but not with body mass index (BMI) or the serum level of tissue-transglutaminase antibodies (tTG). Hypertransaminasemia was detected in 22 patients in cohort B (7%) and was associated with the World Health Organization's BMI categories (OR, 7.9; P < .001). In subsets of patients studied with the same analytical method (313 of cohort A and 188 of cohort B), the level of tTG was significantly higher in cohort A at baseline (25.2 ± 16.9 U/L aspartate aminotransferase [AST]) than in cohort B (20.6 ± 9.9 U/L AST, P < .0001) and was related to BMI in cohort B (P = .0012) but not cohort A. When patients were placed on gluten-free diets, the levels of AST decreased from 25.2 ± 16.9 U/L to 19.9 ± 6.6 U/L (P < .0001), independently of the changes of duodenal histology and tTG and correlated with BMI (P = .0007); the prevalence of hypertransaminasemia decreased from 13% to 4%.
CONCLUSIONS: Patients with celiac disease have a higher prevalence of hypertransaminasemia than controls (patients with functional syndromes). Hypertransaminasemia is related to the severity of the duodenal lesion and malabsorption but not BMI. By contrast, there was a positive correlation between the levels of AST and BMI in controls; this relationship was restored when patients with celiac disease were placed on gluten-free diets.
Copyright © 2014 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Associated Diseases; Clinical Presentation; Gluten Allergy; Liver

Mesh:

Substances:

Year:  2013        PMID: 24211290     DOI: 10.1016/j.cgh.2013.10.033

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  8 in total

1.  Bi-directional Relationship Between Celiac Disease and Liver Chemistries: A Systematic Review and Meta-Analysis.

Authors:  Manik Aggarwal; Rajat Garg; Prabhat Kumar; Christina C Lindenmeyer; Jamile Wakim-Fleming; Claire Jansson-Knodell; Alberto Rubio-Tapia
Journal:  Dig Dis Sci       Date:  2022-08-24       Impact factor: 3.487

2.  Prevalence of abnormal liver function tests in celiac disease and the effect of a gluten-free diet in the US population.

Authors:  Natalia E Castillo; Rohini R Vanga; Thimmaiah G Theethira; Alberto Rubio-Tapia; Joseph A Murray; Javier Villafuerte; Alan Bonder; Rupa Mukherjee; Joshua Hansen; Melinda Dennis; Ciaran P Kelly; Daniel A Leffler
Journal:  Am J Gastroenterol       Date:  2015-07-07       Impact factor: 10.864

3.  Celiac disease in pediatric patients according to HLA genetic risk classes: a retrospective observational study.

Authors:  Carlo Tolone; Marisa Piccirillo; Pasquale Dolce; Salvatore Alfiero; Mattia Arenella; Marina Sarnataro; Patrizia Iardino; Alessia Pucciarelli; Caterina Strisciuglio
Journal:  Ital J Pediatr       Date:  2021-05-05       Impact factor: 2.638

Review 4.  To screen or not to screen? Celiac antibodies in liver diseases.

Authors:  Janaína Luz Narciso-Schiavon; Leonardo Lucca Schiavon
Journal:  World J Gastroenterol       Date:  2017-02-07       Impact factor: 5.742

5.  Liver test abnormalities predict complicated disease behaviour in patients with newly diagnosed Crohn's disease.

Authors:  Jessika Barendregt; Myrthe de Jong; Jeoffrey J Haans; Bart van Hoek; James Hardwick; Roeland Veenendaal; Andrea van der Meulen; Nidhi Srivastava; Rogier Stuyt; Jeroen Maljaars
Journal:  Int J Colorectal Dis       Date:  2016-11-29       Impact factor: 2.571

Review 6.  Extraintestinal Manifestations of Celiac Disease: Early Detection for Better Long-Term Outcomes.

Authors:  Pilvi Laurikka; Samuli Nurminen; Laura Kivelä; Kalle Kurppa
Journal:  Nutrients       Date:  2018-08-03       Impact factor: 5.717

7.  Olmesartan-Induced Enteropathy: An Unusual Cause of Villous Atrophy.

Authors:  Marta Eusébio; Paulo Caldeira; Artur Gião Antunes; André Ramos; Francisco Velasco; Jesús Cadillá; Horácio Guerreiro
Journal:  GE Port J Gastroenterol       Date:  2015-10-20

Review 8.  Celiac Disease and Liver Disorders: From Putative Pathogenesis to Clinical Implications.

Authors:  Iva Hoffmanová; Daniel Sánchez; Ludmila Tučková; Helena Tlaskalová-Hogenová
Journal:  Nutrients       Date:  2018-07-12       Impact factor: 5.717

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.